This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
HAMBURG, Germany, May 7, 2013 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) (ISIN:DE0005664809) will report its financial results for the first quarter of 2013 on Tuesday, 14 May 2013.
The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance:
Conference call details
Tuesday, 14 May 2013
09.30 am CET (08.30 am BST, 3.30 am EDT)
+49 (0) 6103 485 3001
+44 207 153 2027
+1 480 629 9673
A simultaneous slide presentation for participants dialling in
viaphone is available at
www.equitystory.com , password: evotec1112.
To join the
audio webcast and to access the
presentation slides you will find a link on our home page
www.evotec.com shortly before the event.
A replay of the conference call will be available for 24 hours and can be accessed in Europe by dialling +49 69 58 99 90 568 (Germany) or +44 207 959 6720 (UK) and in the US by dialling +1 303 590 3030. The access code is 4615712#. The on-demand version of the webcast will be available on our website:
About Evotec AG
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology and inflammation. Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca and Ono Pharmaceutical. In addition, the Company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships with Boehringer Ingelheim, MedImmune and Andromeda (Teva) in the field of diabetes, with Janssen Pharmaceuticals in the field of depression and with Roche in the field of Alzheimer's disease. For additional information please go to
FORWARD LOOKING STATEMENTS —
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this report. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.
CONTACT: Gabriele Hansen
Head of Corporate Communications
+49.(0)40.560 81-222 Fax
Manfred Eigen Campus
Essener Bogen 7
22419 Hamburg (Germany)